GENERATION OF 5-FLUOROURACIL FROM 5-FLUOROCYTOSINE BY MONOCLONAL-ANTIBODY CYTOSINE DEAMINASE CONJUGATES

被引:79
作者
SENTER, PD [1 ]
SU, PCD [1 ]
KATSURAGI, T [1 ]
SAKAI, T [1 ]
COSAND, WL [1 ]
HELLSTROM, I [1 ]
HELLSTROM, KE [1 ]
机构
[1] UNIV OSAKA PREFECTURE,COLL AGR,SAKAI,OSAKA 591,JAPAN
关键词
D O I
10.1021/bc00012a012
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cytosine deaminase (CDase) catalyzes the conversion of cytosine to uracil and is also able to convert the clinically used antifungal agent 5-fluorocytosine (5FC) into the anticancer drug 5-fluorouracil (5FU). The enzyme was purified from bakers' yeast in a six-step procedure. Studies indicated that bakers' yeast CDase had a molecular weight of approximately 32 kDa and was composed of two subunits of equal molecular weights. Monoclonal antibodies were covalently attached to CDase, forming conjugates that could bind to antigens on tumor cell surfaces. The combination of L6-CDase and 5FC was equivalent in cytotoxic activity to 5FU when tested against the H2981 human lung adenocarcinoma cell line (L6 positive, 1F5 negative). 5FC alone was noncytotoxic. The activation of 5FC was immunologically specific since 1F5-CDase did not enhance 5FC activity.
引用
收藏
页码:447 / 451
页数:5
相关论文
共 27 条
[1]   A CYTO-TOXIC AGENT CAN BE GENERATED SELECTIVELY AT CANCER SITES [J].
BAGSHAWE, KD ;
SPRINGER, CJ ;
SEARLE, F ;
ANTONIW, P ;
SHARMA, SK ;
MELTON, RG ;
SHERWOOD, RF .
BRITISH JOURNAL OF CANCER, 1988, 58 (06) :700-703
[2]   PLASMIN-ACTIVATED PRODRUGS FOR CANCER-CHEMOTHERAPY .1. SYNTHESIS AND BIOLOGICAL-ACTIVITY OF PEPTIDYLACIVICIN AND PEPTIDYLPHENYLENEDIAMINE MUSTARD [J].
CHAKRAVARTY, PK ;
CARL, PL ;
WEBER, MJ ;
KATZENELLENBOGEN, JA .
JOURNAL OF MEDICINAL CHEMISTRY, 1983, 26 (05) :633-638
[3]   ROLE OF THE BP35 CELL-SURFACE POLYPEPTIDE IN HUMAN B-CELL ACTIVATION [J].
CLARK, EA ;
SHU, G ;
LEDBETTER, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (06) :1766-1770
[4]   PRODRUGS IN CANCER-CHEMOTHERAPY [J].
CONNORS, TA .
XENOBIOTICA, 1986, 16 (10-11) :975-988
[5]  
Denny W A, 1988, Drug Des Deliv, V3, P99
[6]  
HEIDELBERGER C, 1975, HDB EXPT PHARMAKOLOG, V38, P193
[7]  
HEIDELBERGER C, 1982, CANCER MED, P801
[8]  
HELLSTROM I, 1986, CANCER RES, V46, P3917
[9]   BAKERS YEAST CYTOSINE DEAMINASE - SOME ENZYMIC PROPERTIES AND ALLOSTERIC INHIBITION BY NUCLEOSIDES AND NUCLEOTIDES [J].
IPATA, PL ;
MARMOCCH.F ;
MAGNI, G ;
FELICIOL.R ;
POLIDORO, G .
BIOCHEMISTRY, 1971, 10 (23) :4270-&
[10]   PURIFICATION AND SOME PROPERTIES OF CYTOSINE DEAMINASE FROM BAKERS-YEAST [J].
KATSURAGI, T ;
SONODA, T ;
MATSUMOTO, K ;
SAKAI, T ;
TONOMURA, K .
AGRICULTURAL AND BIOLOGICAL CHEMISTRY, 1989, 53 (05) :1313-1319